InvestorsHub Logo
Followers 36
Posts 4844
Boards Moderated 1
Alias Born 06/27/2003

Re: None

Saturday, 01/07/2017 2:14:07 PM

Saturday, January 07, 2017 2:14:07 PM

Post# of 138
Jan 04, 2017 (Marketwired via COMTEX) -- SAN FRANCISCO, CA--(Marketwired - January 04, 2017) - Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco on January 11.

Included in this article are: Actinium Pharmaceuticals Inc. (nyse mkt:ATNM) Asterias Biotherapeutics Inc. (nyse mkt:AST)

The collection of small-cap biotechs on the 2017 Watchlist are developing therapies to address diverse indications including rare diseases, asthma, inflammatory bowel disease, spinal cord injury, hemophilia, and a number of cancers. The platforms are equally diverse, representing traditional biologics, cell therapies and vaccines. Watchlist companies include:

Asterias Biotherapeutics Inc. : ~$226M market cap. This stem cell company is addressing two key markets: spinal cord injury and cancer, with a dendritic cell (DC) therapy using genetically engineered autologous and allogeneic stem cells.